0001225208-11-016910.txt : 20110630
0001225208-11-016910.hdr.sgml : 20110630
20110630155329
ACCESSION NUMBER: 0001225208-11-016910
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20110622
FILED AS OF DATE: 20110630
DATE AS OF CHANGE: 20110630
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: von Autenried Paul
CENTRAL INDEX KEY: 0001524143
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-01136
FILM NUMBER: 11942205
MAIL ADDRESS:
STREET 1: BRISTOL-MYERS SQUIBB COMPANY
STREET 2: 100 NASSAU PARK BOULEVARD
CITY: PRINCETON
STATE: NJ
ZIP: 08543
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO
CENTRAL INDEX KEY: 0000014272
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 220790350
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVE
CITY: NEW YORK
STATE: NY
ZIP: 10154
BUSINESS PHONE: 2125464000
MAIL ADDRESS:
STREET 1: 345 PARK AVE
CITY: NEW YORK
STATE: NY
ZIP: 10154
FORMER COMPANY:
FORMER CONFORMED NAME: BRISTOL MYERS CO
DATE OF NAME CHANGE: 19891012
3
1
doc3.xml
X0203
3
2011-06-22
0
0000014272
BRISTOL MYERS SQUIBB CO
BMY
0001524143
von Autenried Paul
345 PARK AVENUE
NEW YORK
NY
10154
1
SVP & CIO
Common Stock, $0.10 par value
20671.0000
D
Market Share Units
2015-03-01
Common Stock, $0.10 par value
12726.0000
D
Market Share Units
2014-03-02
Common Stock, $0.10 par value
5307.0000
D
Option (right to buy)
17.5100
2019-03-02
Common Stock, $0.10 par value
51504.0000
D
Option (right to buy)
22.1400
2018-03-03
Common Stock, $0.10 par value
21049.0000
D
Option (right to buy)
27.0100
2017-03-05
Common Stock, $0.10 par value
15663.0000
D
Option (right to buy)
28.1100
2014-03-01
Common Stock, $0.10 par value
19500.0000
D
Option (right to buy)
48.0750
2012-03-04
Common Stock, $0.10 par value
13000.0000
D
Performance Shares
2012-03-31
Common Stock, $0.10 par value
7286.0000
D
Performance Shares
2013-03-31
Common Stock, $0.10 par value
4496.0000
D
Restricted Stock Units
2013-03-03
Common Stock, $0.10 par value
4844.0000
D
Restricted Stock Units
2012-03-04
Common Stock, $0.10 par value
1155.0000
D
Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date, starting on March 1, 2012, and upon vesting will be converted into shares of common stock based on a conversion factor.
Each market share unit converts into the number of shares of common stock based on the average of the closing share price of the company's common stock on the vesting date and the nine trading days immediately preceding the vesting date.
1,769 market share units will vest on each of March 2, 2012, March 2, 2013, and March 2, 2014 and upon vesting will be converted into shares of common stock based on a conversion factor.
25,752 shares are currently exerciseable. 12,876 shares will become exerciseable on each of March 3, 2012 and March 3, 2013.
15,786 are currently exerciseable. The remaining 5,263 shares will become exerciseable on March 4, 2012.
Currently Exercisable.
Consists of performance shares earned under the 2009-2011 Long Term Performance Award with a payout during the first quarter of 2012.
Each performance share converts into one share of common stock upon payout.
Consists of 4,228 performance shares and 268 performance shares representing dividend equivalents earned under the 2010-2012 Long Term Performance Award with a payout during the first quarter of 2013.
2,422 restricted stock units will vest on each of March 3, 2012 and March 3, 2013 and upon vesting will be converted to shares of common stock.
Each restricted stock unit converts into one share of common stock upon vesting.
These restricted stock units will vest on March 4, 2012 and upon vesting will be converted into shares of common stock.
vonautenriedpoa.txt
/s/ Paul von Autenried
2011-06-30
EX-24
2
vonautenriedpoa.txt
POWER OF ATTORNEY
I, Paul von Autenried, Senior Vice President and Chief Information
Officer of Bristol-Myers Squibb Company, a corporation duly
organized and existing under the laws of the State of Delaware, in the
United States of America, and having its principal place of business
at 345 Park Avenue, New York, New York, do hereby constitute and
appoint each of Sandra Leung and and Katherine Kelly, individually,
as my lawful attorney-in-fact and in my name, place and stead to
execute and deliver any and all documents relating to insider
reporting requirements under Section 16 of the Securities Exchange Act
of 1934, including, without limitation, the execution and filing of all
Forms 3, 4 and 5, and to take such other action, as such attorney
considers necessary or appropriate, to effectuate such transactions
until such time as I am no longer an officer of Bristol Myers Squibb
Company.
IN WITNESS WHEREOF, I have executed this Power of Attorney on this 23rd
day of June, 2011.
/s/ Paul von Autenried
Paul von Autenried